702 related articles for article (PubMed ID: 21163137)
21. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Scheithauer W; Kornek GV; Brugger S; Ullrich-Pur H; Valencak J; Raderer M; Fiebiger W; Kovats E; Lang F; Depisch D
Cancer Invest; 2002; 20(1):60-8. PubMed ID: 11853004
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
Park SH; Sung JY; Han SH; Baek JH; Oh JH; Bang SM; Cho EK; Shin DB; Lee JH
Jpn J Clin Oncol; 2005 Sep; 35(9):531-5. PubMed ID: 16027146
[TBL] [Abstract][Full Text] [Related]
25. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
[TBL] [Abstract][Full Text] [Related]
26. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
27. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
[TBL] [Abstract][Full Text] [Related]
28. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Rothenberg ML; Oza AM; Bigelow RH; Berlin JD; Marshall JL; Ramanathan RK; Hart LL; Gupta S; Garay CA; Burger BG; Le Bail N; Haller DG
J Clin Oncol; 2003 Jun; 21(11):2059-69. PubMed ID: 12775730
[TBL] [Abstract][Full Text] [Related]
29. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
30. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
Sunakawa Y; Fujita K; Ichikawa W; Ishida H; Yamashita K; Araki K; Miwa K; Kawara K; Akiyama Y; Yamamoto W; Nagashima F; Saji S; Sasaki Y
Oncology; 2012; 82(4):242-8. PubMed ID: 22508373
[TBL] [Abstract][Full Text] [Related]
32. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.
Ashley AC; Sargent DJ; Alberts SR; Grothey A; Campbell ME; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Goldberg RM
Cancer; 2007 Aug; 110(3):670-7. PubMed ID: 17559146
[TBL] [Abstract][Full Text] [Related]
33. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
Dy GK; Krook JE; Green EM; Sargent DJ; Delaunoit T; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pockaj BA; Sticca RP; Alberts SR; Pitot HC; Goldberg RM;
J Clin Oncol; 2007 Aug; 25(23):3469-74. PubMed ID: 17687151
[TBL] [Abstract][Full Text] [Related]
34. [Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer].
Committee of Colorectal Cancer, Chinese Southern Oncology Group
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Jun; 24(6):473-479. PubMed ID: 34148311
[TBL] [Abstract][Full Text] [Related]
35. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Grothey A; Sargent D; Goldberg RM; Schmoll HJ
J Clin Oncol; 2004 Apr; 22(7):1209-14. PubMed ID: 15051767
[TBL] [Abstract][Full Text] [Related]
36. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Folprecht G; Köhne CH
Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
[TBL] [Abstract][Full Text] [Related]
37. FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
Kim JH; Park SJ; Park MI; Moon W; Kim SE; Ku KH; Song SE; Kim JH
Korean J Gastroenterol; 2014 Jan; 63(1):18-24. PubMed ID: 24463284
[TBL] [Abstract][Full Text] [Related]
38. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
[TBL] [Abstract][Full Text] [Related]
39. Second-line therapy in colorectal cancer.
Berlin J
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):21-6. PubMed ID: 11204658
[TBL] [Abstract][Full Text] [Related]
40. [Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].
Song Y; Li WW; Huang J
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):380-383. PubMed ID: 28535657
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
